ClinicalTrials.gg
RecruitingNCT07224776Updated Jul 30, 2026

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

A Phase 1 interventional study of sparsentan and No sparsentan in Proteinuric Renal Disease, Proteinuric Kidney Disease and Proteinuria, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Brigham and Women's Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Proteinuria with a site in United States — 20 open to participants now, 25 under way, 9 of them phase 3. Proteinuria · United States.

Planned enrollment
60th of 97
20 · median 30
Started
2026
with 7 others
Phase 1
9 of 126
2 open now
Primary completion
2026-12
later than 2 of 23 live
Registered
118th of 126
by date
Lead sponsor
2 of 126
Brigham and Women's Hospital

Among the 126 studies in Proteinuria with a site in United States, this one is the 60th largest by planned enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 2 of the 23 other live ones, and was the 118th registered.

Proteinuria

330 studies on the registry are indexed under Proteinuria; 45 are open to participants now.

Browse Proteinuria studies →

Open to participants now

20 of the 126 studies in Proteinuria with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Proteinuria studies recruiting now, 13 (39%) set no upper age limit and 16 (48%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Proteinuria with a site in United States, or all of them as a file.
02

Study summary

Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors

03

Conditions studied

  • Proteinuric Renal Disease
  • Proteinuric Kidney Disease
  • Proteinuria
  • Proteinuria in Nephrotic Range

Keywords

  • vascular endothelial growth factor inhibitors
  • cancer
  • proteinuria
  • endothelin-1 antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥ 18 years old) with active who are currently treated with VSPIs
  2. New high-grade proteinuria, defined as ≥ 2+ proteinuria on dipstick or a calculated urinary protein-to-creatinine ratio ≥ 1.0 g/g
  3. Able to provide written inform consent

Exclusion criteria

Exclusion Criteria:

  1. Estimated (eGFR) \< 45 ml/min/1.73m2
  2. Baseline high grade proteinuria ≥ 2+ proteinuria on dipstick or a calculated urinary protein-to creatinine ratio or microalbumin-to-creatinine ≥ 1.0 g/g prior to VSPI initiation
  3. Acute kidney injury defined as serum creatinine at least 1.5 times above the most proximal serum creatinine prior to VSPIs initiation
  4. History of allergic reactions or angioedema to any angiotensin receptor blocker (ARB) or ERA, including sparsentan or irbesartan, or has a to any of the in the study medications.
  5. Any potassium value >5 mEq/L in the 14 days preceding high-grade proteinuria
  6. History of organ transplantation, with the exception of corneal transplants.
  7. History of congestive heart failure ( Class II-IV)
  8. History of cerebrovascular disease ( or stroke) and/or coronary artery disease (hospitalization for myocardial infarction or unstable angina, new onset of angina with positive functional tests, coronary angiogram revealing stenosis, or a coronary revascularization procedure) within 6 months prior to screening.
  9. Jaundice, hepatitis, or known hepatobiliary disease (excluding asymptomatic cholelithiasis), or and/or aspartate aminotransferase >2 times the at screening.
  10. Body weight \<50 kg at screening
  11. Unable to hold renin-angiotensin-aldosterone system (RAAS) inhibitors such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), spironolactone, eplerenone, aliskiren, aldosterone blockers during run-in period
  12. Concomitant use of the following medications:

    1. Inhibitors of endothelin system such as ambrisentan, bosentan, macitentan
    2. Potassium-sparing diuretics such as amiloride, triamterene
    3. Antiarrhythmic medications such as amiodarone, digoxin
    4. Weight loss medications such as orlistat or amphetamine derivative agents
    5. St. John's wort or other hypericum-derived products
    6. Strong inhibitors such as ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, ritonavir- or cobicistat-boosted regimens, boceprevir, telaprevir, conivaptan, mibefradil
  13. Pregnant or breastfeeding
  14. Concurrent participation in a study with an alternative experimental therapy that may interact with sparsentan
  15. Any condition that, in the view of the principal investigator, might place the patient at increased risk or compromise the integrity of the study
  16. Conflict with other study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Treatment with sparsentan, an endothelin-1 antagonist

    Participants will receive sparsentan 200 mg daily for 2 weeks, and will then titrate up to a target of 400 mg daily. After the Week 8 visit, patients will return to standard-of-care. We will compare the mean percent change in urine protein to creatinine ratio in patients treated with sparsentan versus historical controls who did not receive sparsentan.

    Drug: sparsentan

  • Placebo comparator
    Historical controls with high-grade proteinuria not treated with sparsentan

    Participants must meet all eligibility criteria, but did not receive sparsentan. Historical controls will be matched based on age, sex, race, stage and cancer type

    Drug: No sparsentan

Interventions

  • Participants will receive sparsentan 200 mg daily for 2 weeks, and will then titrate up to a target of 400 mg daily. Safety and feasibility will be assessed. The mean percent change in urine protein to creatinine ratio will be assessed from screening to week 8, and compared to historical controls not treated with sparsentan.

  • DrugNo sparsentan

    Historical controls who did not receive sparsentan, and are matched to patients who are treated with sparsentan

06

What researchers measure

Primary outcomes

  1. Change in urine to protein creatinine ratio (UPCR)

    The geometric mean percent change in UPCR from screening day to Week 8

    Time frame: 8 weeks

Secondary outcomes

  1. VSPI discontinuation or interruption

    Incidence of VSPI discontinuation or interruption in the 8 weeks following onset of high-grade proteinuria

    Time frame: 8 weeks

  2. Resolution of Proteinuria

    Incidence of resolution of high-grade proteinuria, defined as recovery of UPCR \< 0.5 g/g in the 8 weeks following onset of high-grade proteinuria

    Time frame: 8 weeks

Other outcomes

  1. Incidence of treatment-related adverse events including any of the following events

    1. Hyperkalemia defined as serum potassium ≥ 5.5 mmol/L on two separate occasion after ruling out measurement errors and alternative causes and despite appropriate use of diuretics and dietary modification 2. Hypotension defined as decrease in systolic blood pressure ≥20 mm Hg or diastolic blood pressure by ≥10 mm Hg from pre-sparsentan baseline with new dizziness after excluding alternative causes unrelated to sparsentan or determined at the discretion of treating physician 3. AKI defined as serum creatinine persistently ≥ 1.5-fold from pre-sparsentan baseline on 2 consecutive lab checks after excluding alternative causes unrelated to sparsentan or determined at the discretion of treating physician 4. Elevated liver function test defined as newly developed AST or ALT ≥ 3 times of the ULN, with or without an elevation of total serum bilirubin ≥ 2 times ULN after sparsentan initiation

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This is a small, pilot study with patients with cancer receiving a specific cancer treatment.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Nov 5, 2025
StartActual
Jul 10, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07224776
Collaborators
Travere Therapeutics, Inc.
Responsible party
Shruti Gupta (Director of Onconephrology, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 5, 2025
Start date
Jul 10, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Shruti Gupta, MD, MPH
Contact
sgupta21@bwh.harvard.edu
5712366626
Api Chewcharat, MD, MPH
Contact
achewcharat@bwh.harvard.edu
857-930-5167

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion